Coherus Oncology, Inc. (CHRS)

Market Cap	94.16M
Revenue (ttm)	272.25M
Net Income (ttm)	-130.94M
Shares Out	115.93M
EPS (ttm)	-1.14
PE Ratio	1.91
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,331,726
Open	0.7664
Previous Close	0.7462
Day's Range	0.7576 - 0.8200
52-Week Range	0.6603 - 2.4300
Beta	0.87
Analysts	Buy
Price Target	4.68 (+476.21%)
Earnings Date	Aug 7, 2025

About CHRS

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 mono...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 6, 2014
• Employees: 228
• Stock Exchange: NASDAQ
• Ticker Symbol: CHRS
• Website: https://www.coherus.com

Analyst Summary

According to 3 analysts, the average rating for CHRS stock is "Buy." The 12-month stock price target is $4.68, which is an increase of 476.21% from the latest price.

Price Target

$4.68

(476.21% upside)

Analyst Consensus: Buy